Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation


Our health care system is complex. There are many key decision makers at either federal, national or provincial levels that are responsible for the health care services Canadians receive from coast to coast. Myeloma Canada has partnered with other patient organizations and coalitions to drive change towards a more favourable patient-focused environment:

  • "Recommendations on Proposed Amendments to the Patented Medicines Regulations" co-written by Myeloma Canada and endorsed by 16 other patient organizations in June 2017.
  • On February 14, 2018 Myeloma Canada and 27 other patient organizations sent their recommendations to the Health Canada consultation process on the proposed changes to the PMPRB guidelines under the Canada Gazette-Part 1 process. Our submission can be found here.
  • In April 2018, 13 patient organizations including Myeloma Canada signed and affirmed their position on a whitepaper called "Improving Access to Innovative Therapies in Canada". In this paper, we argue that there is a gap in access to innovative new cancer drug therapies, effectively denying or delaying potentially life-saving treatment for many cancer patients in Canada.
  • Internationally, Myeloma Canada is founding member of the Global Myeloma Action Network (GMAN). The Global Myeloma Action Network brings together advocacy leaders to mobilize the myeloma community to improve the lives of patients around the world.